|1.||Mash, D C: 4 articles (07/2006 - 09/2000)|
|2.||Hilber, Karlheinz: 3 articles (01/2015 - 12/2013)|
|3.||Koenig, Xaver: 3 articles (01/2015 - 12/2013)|
|4.||Leal, M B: 3 articles (07/2006 - 08/2000)|
|5.||Elisabetsky, E: 3 articles (07/2006 - 08/2000)|
|6.||Glick, S D: 3 articles (09/2000 - 01/2000)|
|7.||Maisonneuve, I M: 3 articles (09/2000 - 01/2000)|
|8.||Kovar, Michael: 2 articles (03/2014 - 12/2013)|
|9.||Sandtner, Walter: 2 articles (03/2014 - 12/2013)|
|10.||Alper, Kenneth R: 2 articles (03/2012 - 01/2008)|
|1.||Substance-Related Disorders (Drug Abuse)
09/01/2000 - "Ibogaine has shown preliminary efficacy for opiate detoxification and for short-term stabilization of drug-dependent persons as they prepare to enter substance abuse treatment. "
09/01/2000 - "The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. "
09/01/1996 - "The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. "
07/01/1994 - "Ibogaine may be of value in the present and could serve as a model for the development of improved agents for the treatment of substance abuse in the future."
03/01/2013 - "This article reviews the history of ibogaine's use in the treatment of drug addiction, and discusses progress made towards, and obstacles blocking, the establishment of controlled clinical trials of ibogaine's efficacy. "
|2.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/01/1997 - "Ibogaine is a natural alkaloid of Voacanga africana that is effective in the treatment of withdrawal symptoms and craving in drug addicts. "
06/01/2004 - "Furthermore, both anecdotal observations and recent studies suggest that ibogaine alleviates withdrawal symptoms and reduces drug cravings. "
03/01/2013 - "Preclinical research has generally supported anecdotal claims that ibogaine attenuates withdrawal symptoms and reduces drug cravings. "
07/10/2006 - "The simplification of the ibogaine structure appears as a promising approach toward the design of compounds that could reduce the withdrawal symptoms."
09/01/2000 - "Anecdotal reports attest that a single dose of ibogaine eliminates opiate withdrawal symptoms and reduces drug craving for extended periods of time. "
|3.||Cocaine-Related Disorders (Cocaine Addiction)
05/30/1998 - "Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. "
09/14/1993 - "These results indicate that ibogaine or its metabolite(s) is a long-lasting interruptor of cocaine dependence, which supports similar observations from uncontrolled clinical studies."
08/01/1998 - "Ibogaine is a psychoactive alkaloid that possesses potential as an agent to treat opiate and cocaine addiction. "
07/01/1993 - "Reports that ibogaine may have potent anti-addictive properties have led to initiatives that it be tested for the treatment of opiate and cocaine addiction. "
03/03/1992 - "Although high doses of cocaine can become aversive by producing an anxiogenic reaction, it is unknown whether the potentiation of cocaine's effects by ibogaine would also cause aversion and lead to a decrease in cocaine addiction."
09/01/2000 - "Ibogaine produces whole body tremors and, at high doses (> or = 100 mg/kg), cerebellar damage; 18-MC does not produce these effects. "
01/01/2000 - "Ibogaine produces whole body tremors and, at high doses (at least 100 mg/kg), cerebellar damage; 18-MC does not produce these effects. "
05/01/1992 - "Although there was a complete absence of tremors, ibogaine still significantly reduced the occurrence of the same four signs of withdrawal."
05/01/1992 - "Ibogaine induces head and body tremors lasting for 2-3 hr and the tremors might have interfered with the expression of opioid withdrawal. "
04/03/1991 - "Ibogaine dose dependently (2.5-80 mg/kg) decreased morphine intake in the hour after ibogaine treatment (acute effect) and, to a lesser extent, a day later (aftereffect); while the acute effect could be attributed to abnormal motor behavior (whole body tremors), the aftereffect occurred at a time when ibogaine should have been entirely eliminated from the body and when there was no obvious indication of ibogaine exposure. "
01/01/2015 - "Knowledge of the side effects of ibogaine has mainly come from reports of cardiovascular complications; seizures are rarely mentioned and experimental findings are inconsistent. "
01/01/2015 - ""Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report."
08/01/2000 - "Ibogaine (80 mg/kg, ip) was effective in inhibiting convulsions induced by NMDA at 24 and 72 hours post administration. "
08/01/2000 - "Long-lasting ibogaine protection against NMDA-induced convulsions in mice."
03/01/2012 - "Other apparent risk factors include seizures associated with withdrawal from alcohol and benzodiazepines and the uninformed use of ethnopharmacological forms of ibogaine."
|4.||Morphine (MS Contin)
|6.||kappa Opioid Receptors (kappa Opioid Receptor)
|7.||Lysergic Acid Diethylamide (LSD)
|10.||Ion Channels (Ion Channel)
|1.||Drug Therapy (Chemotherapy)
|2.||Complementary Therapies (Alternative Medicine)